ProQR Therapeutics (PRQR) Stock Forecast: StockMap's 2-Week Call
PRQR stock forecast: StockMap's model leans Underperform on ProQR Therapeutics for the two weeks after the Nov 19 close, toward PRQR trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 3 of 4 two-week windows on PRQR since Sep 24; by chance, a call on the same dates was right 53% of the time.
ProQR Therapeutics last closed at $1.05, -4.55% on the session.
Against the IVW growth benchmark the position is -2.22% over the forecast window.
ProQR Therapeutics' market cap is $148.39M as of November 19, 2026.
Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -42 (too close to call).
Where PRQR sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 1 bullish and 14 bearish.
Agreement across those insights is 93%.
26 daily calls for PRQR so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks ProQR Therapeutics in the 14th percentile on return on equity, where 100 is best.
ProQR Therapeutics is classified under Health Care / Biotechnology.
StockMap tracks ProQR Therapeutics as the 251st largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.
On that composite ProQR Therapeutics ranks 316th of 394 in the group, against a group median of -0.27.